Literature DB >> 20977343

IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.

Maureen P Martin1, Ying Qi, James J Goedert, Shehnaz K Hussain, Gregory D Kirk, W Keith Hoots, Susan Buchbinder, Mary Carrington, Chloe L Thio.   

Abstract

An IL28B haplotype strongly determines the outcome of natural and interferon-α treated hepatitis C virus (HCV) infection. To assess whether the polymorphism marking the haplotype (rs12979860) also affects other interferon-α responsive chronic viral illnesses, namely hepatitis B virus (HBV) and human immunodeficiency virus (HIV) type 1 infections, we genotyped 226 individuals with HBV persistence, 384 with HBV recovery, and 2548 with or at high risk for HIV infection. The C/C genotype of rs12979860 was not associated with HBV recovery (odds ratio, 0.99), resistance to HIV infection (odds ratio, 0.97), or HIV disease progression (P > .05). This IL28B single-nucleotide polymorphism affects the immune response to HCV but not to HBV or HIV.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20977343      PMCID： PMC2974014          DOI： 10.1086/657146

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases.

Authors: 
Journal:  MMWR Suppl       Date:  1987-08-14

2.  Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.

Authors:  C Lapenta; S M Santini; E Proietti; P Rizza; M Logozzi; M Spada; S Parlato; S Fais; P M Pitha; F Belardelli
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

3.  Lambda interferon inhibits hepatitis B and C virus replication.

Authors:  Michael D Robek; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.

Authors:  Tobias Marcello; Arash Grakoui; Giovanna Barba-Spaeth; Erica S Machlin; Sergei V Kotenko; Margaret R MacDonald; Charles M Rice
Journal:  Gastroenterology       Date:  2006-10-01       Impact factor: 22.682

5.  Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.

Authors:  Chloe L Thio; Jacquie Astemborski; Arman Bashirova; Timothy Mosbruger; Spencer Greer; Mallory D Witt; James J Goedert; Margaret Hilgartner; Audrey Majeske; Stephen J O'Brien; David L Thomas; Mary Carrington
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells.

Authors:  Seung-Ho Hong; Okki Cho; Koyngmin Kim; Ho-Joon Shin; Sergei V Kotenko; Sun Park
Journal:  Virus Res       Date:  2007-04-23       Impact factor: 3.303

7.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

8.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1992-12-18

9.  Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages.

Authors:  Wei Hou; Xu Wang; Li Ye; Lin Zhou; Zhan-Qiu Yang; Eric Riedel; Wen-Zhe Ho
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

10.  Common genetic variation and the control of HIV-1 in humans.

Authors:  Jacques Fellay; Dongliang Ge; Kevin V Shianna; Sara Colombo; Bruno Ledergerber; Elizabeth T Cirulli; Thomas J Urban; Kunlin Zhang; Curtis E Gumbs; Jason P Smith; Antonella Castagna; Alessandro Cozzi-Lepri; Andrea De Luca; Philippa Easterbrook; Huldrych F Günthard; Simon Mallal; Cristina Mussini; Judith Dalmau; Javier Martinez-Picado; José M Miro; Niels Obel; Steven M Wolinsky; Jeremy J Martinson; Roger Detels; Joseph B Margolick; Lisa P Jacobson; Patrick Descombes; Stylianos E Antonarakis; Jacques S Beckmann; Stephen J O'Brien; Norman L Letvin; Andrew J McMichael; Barton F Haynes; Mary Carrington; Sheng Feng; Amalio Telenti; David B Goldstein
Journal:  PLoS Genet       Date:  2009-12-24       Impact factor: 5.917
View more
  46 in total

1.  Frequency of interleukin 28B rs12979860 C>T variants in Filipino patients chronically infected with hepatitis B virus.

Authors:  Michael O Baclig; Karen G Reyes; Cynthia A Mapua; Juliet Gopez-Cervantes; Filipinas F Natividad
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

Review 2.  Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Authors:  Tzu-Hao Lee; Hans L Tillmann; Keyur Patel
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

3.  Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors.

Authors:  Maria Salgado; Gregory D Kirk; Andrea Cox; Alleluiah Rutebemberwa; Yvonne Higgins; Jacquie Astemborski; David L Thomas; Chloe L Thio; Mark S Sulkowski; Joel N Blankson
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

4.  IL28B genotype does not correlate with HIV control in African Americans.

Authors:  Mohammad M Sajadi; Nahzinine Shakeri; Rohit Talwani; Charles D Howell; Ruth Pakyz; Robert R Redfield; Afshin Parsa
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

5.  Chronic hepatitis B and IL28B rs12979860 polymorphism: preliminary study.

Authors:  Özlem Kandemir; Senay Balcı Fidancı; Neslihan Demir; Ayşegül Görür; Lülüfer Tamer
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

6.  IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes.

Authors:  Fuat Kurbanov; Yonghak Kim; Rachel Latanich; Pooja Chaudhari; Ramy El-Diwany; Matt Knabel; Abraham J Kandathil; Andrew Cameron; Andrea Cox; Yoon-Young Jang; David L Thomas; Ashwin Balagopal
Journal:  Antivir Ther       Date:  2015-06-25

7.  The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection.

Authors:  K Domagalski; M Pawłowska; A Zaleśna; M Tyczyno; M Skorupa-Kłaput; A Tretyn; W Halota
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-13       Impact factor: 3.267

Review 8.  Interleukin 28B genetic polymorphism and hepatitis B virus infection.

Authors:  Toru Takahashi
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

9.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

Review 10.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.